HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How To Get A ‘Great Britain’ Drug Approval In 2021

Executive Summary

So much will change on the regulatory front next year that the UK drug regulator, the MHRA, has had to issue dozens of new guidance documents to help pharma and biotech firms navigate the new requirements and assessment routes. A key consideration is how the UK will handle centralized EU applications that are still pending on 31 December.

You may also be interested in...



Global Pharma Guidance Tracker – July 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit

The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit. 

Coronavirus Notebook: UK To Run Vaccine Challenge Studies, CEPI Expands Manufacturing Network

Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.

Topics

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel